Bloomberg Article
'Andrew Hopkins, chief executive officer of Oxford, England-based startup Exscientia Ltd is among those working to help train artificial intelligence for drug discovery. He figures new treatments could go from conception to clinical testing in as little as 18 to 24 months within the next decade, thanks to AI'.